aa-IPI; DLBCL; radiotherapy; Rituximab; primary bone lymphoma
Abstract :
[en] Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We
treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained complete remission rate and a 78.9% survival over a 4.7-year median follow-up period. Ann Arbor stage IV and high age-adjusted international prognostic index were predictive of adverse outcome in univariate analysis. In multivariate analysis using a Cox model, only aa-IPI predicted long-term survival. While based on a limited number of cases, we suggested that radiotherapy may be useful as a consolidation modality in PB-DLBCL. We also suggested that positron emission tomography/CT scan should be interpreted with caution due to a persistent [18F]fluorodeoxyglucose [18FDG] uptake of bone lesions even after remission in some in PB-DLBCL patients. Our study based on a homogeneous cohort of PB-DLBCL patients confirmed the favorable outcome of this DLBCL variant and support the implementation of prospective clinical trials in this disease.
P.Dubey, C.S.Ha, P.C.Besa,. Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys. 1997;37:1087–1093.
D.Limb, C.Dreghorn, J.K.Murphy,. Primary lymphoma of bone. Int Orthop. 1994;18:180–183.
P.P.Carbone, H.S.Kaplan, K.Musshoff,. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;31:1860–1861.
T.A.Lister, D.Crowther, S.B.Sutcliffe,. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting. J Clin Oncol. 1989;7:1630–1636.
K.M.Ramadan, T.Shenkier, L.H.Sehn,. A clinicopathological retrospective study of 131 patients with primary bone lymphoma:a population-based study of successively treated cohorts from the British Columbia cancer agency. Ann Oncol. 2007;18:129–135.
A.Alencar, D.Pitcher, G.Byrne,. Primary bone lymphoma-the university of Miami experience. Leuk Lymphoma. 2010;51:39–49.
K.Beal, L.Allen, J.Yahalom Primary bone lymphoma:treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer. 2006;106:2652–2656.
S.Bhagavathi, M.A.Micale, K.Les,. Primary bone diffuse large B-cell lymphoma:clinicopathologic study of 21 cases and review of literature. Am J Surg Pathol. 2009;33:1463–1469.
F.H.Heyning, P.C.Hogendoorn, M.H.Kramer,. Primary lymphoma of bone:extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. J Clin Pathol. 2009;62:820–824.
L.Cai, M.C.Stauder, Y.J.Zhang,. Early-stage primary bone lymphoma:a retrospective, multicenter rare cancer network (RCN) study. Int J Radiat Oncol Biol Phys. 2012;83:284–291.
P.L.Zinzani, G.Carrillo, S.Ascani,. Primary bone lymphoma:experience with 52 patients. Haematologica. 2003;88:280–285.
C.Messina, D.Christie, E.Zucca,. Primary and secondary bone lymphomas. Cancer Treat Rev. 2015;41:235–246.
A.J.Rathmell, M.K.Gospodarowicz, S.B.Sutcliffe,. Localised lymphoma of bone:prognostic factors and treatment recommendations. The princess Margaret hospital lymphoma group. Br J Cancer. 1992;66:603–606.
R.Tao, P.K.Allen, A.Rodriguez,. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015;92:122–129.
N.Ketterer, B.Coiffier, C.Thieblemont,. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol. 2013;24:1032–1037.
C.Recher, B.Coiffier, C.Haioun,. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B):an open-label randomised phase 3 trial. Lancet. 2011;378:1858–1867.
O.Fitoussi, K.Belhadj, N.Mounier,. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011;96:1136–1143.
R.Delarue, H.Tilly, N.Mounier,. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study):a randomised phase 3 trial. Lancet Oncol. 2013;14:525–533.
F.Peyrade, F.Jardin, C.Thieblemont,. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma:a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–468.
C.Copie-Bergman, P.Gaulard, K.Leroy,. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP:a GELA study. J Clin Oncol. 2009;27:5573–5579.
F.Reyes, E.Lepage, G.Ganem,. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197–1205.
C.P.Hans, D.D.Weisenburger, T.C.Greiner,. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
H.Tilly, E.Lepage, B.Coiffier,. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–4289.
B.Coiffier, E.Lepage, J.Briere,. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
Fletcher CDM, Krishnan UK, F.Mertens Pathology and genetics of tumors of soft tissue and bone:World Health Organization classification of tumours. Lyon, France:IARC Press; 2002.
E.Campo, S.H.Swerdlow, N.L.Harris,. The 2008 WHO classification of lymphoid neoplasms and beyond:evolving concepts and practical applications. Blood. 2011;117:5019–5032.
C.Messina, A.J.Ferreri, S.Govi,. Clinical features, management and prognosis of multifocal primary bone lymphoma:a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). Br J Haematol. 2014;164:834–840.
C.Mamot, D.Klingbiel, F.Hitz,. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33:2523–2529.
A.P.Ng, A.Wirth, J.F.Seymour,. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma:isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma. 2007;48:596–600.
J.A.Vargo, B.S.Gill, G.K.Balasubramani,. Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma:do we still need consolidative radiotherapy? J Clin Oncol. 2015;33:3710–3717.
G.Held, S.Zeynalova, N.Murawski,. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31:4115–4122.
E.Barbieri, S.Cammelli, F.Mauro,. Primary non-Hodgkin's lymphoma of the bone:treatment and analysis of prognostic factors for Stage I and Stage II. Int J Radiat Oncol Biol Phys 2004;59:760–764.
H.Wu, L.Zhang, H.Shao,. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma:a single institutional experience. Br J Haematol. 166:60–68.
M.Bruno Ventre, A.J.Ferreri, M.Gospodarowicz,. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist. 19:291–298.